Compare QNST & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QNST | DRUG |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | 25 |
| Industry | Business Services | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 870.0M | 707.1M |
| IPO Year | 2009 | 2020 |
| Metric | QNST | DRUG |
|---|---|---|
| Price | $12.16 | $72.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $24.75 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 828.8K | 78.6K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $282,140,000.00 | N/A |
| Revenue This Year | $18.59 | N/A |
| Revenue Next Year | $14.96 | N/A |
| P/E Ratio | $12.59 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.29 | $23.18 |
| 52 Week High | $19.53 | $123.75 |
| Indicator | QNST | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 37.05 |
| Support Level | $10.79 | $72.06 |
| Resistance Level | $12.62 | $91.00 |
| Average True Range (ATR) | 0.46 | 4.68 |
| MACD | 0.16 | -1.03 |
| Stochastic Oscillator | 75.41 | 15.05 |
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.